Expression of p-AKT and p-mTOR in a large series of bronchopulmonary neuroendocrine tumors

Experimental and Therapeutic Medicine

Volumn 2, Issue 5, 2011, Pages 787-792

  Alì, Greta ^a   Boldrini, Laura ^a   Capodanno, Alessandra ^a   Pelliccioni, Serena ^a   Servadio, Adele ^a   Crisman, Giuliana ^b   Picchi, Alessandro ^a   Davini, Federico ^a   Mussi, Alfredo ^a   Fontanini, Gabriella ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

AKT mammalian target of rapamycin pathway; Bronchopulmonary neuroendocrine tumors; Immunohistochemistry

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHOPROTEIN; PROTEIN KINASE B;

ADULT; AGED; ARTICLE; ATYPICAL CARCINOID TUMOR; BRONCHUS CARCINOID; CANCER GRADING; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG TARGETING; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG SMALL CELL CANCER; LUNG TUMOR; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR VOLUME;

EID: 79960281097     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.291     Document Type: Article

References (34)

1. Travis WD, Brambilla E, Muller-Hermelink HK and Harris CC: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press, Lyon, 2004.
2. Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA and Koss MN: Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 22: 934-944, 1998.
3. Canessa PA, Santini D, Zanelli M and Capecchi V: Pulmonary tumourlets and microcarcinoids in bronchiectasis. Monaldi Arch Chest Dis 52: 138-139, 1997.
4. Watanabe H, Kobayashi H, Honma K, Ohnishi Y and Iwafuchi M: Diffuse panbronchiolitis with multiple tumorlets. A quantitative study of the Kultschitzky cells and the clusters. Acta Pathol Jpn 35: 1221-1231, 1985.
5. Granberg D, Wilander E, Oberg K and Skogseid B: Prognostic markers in patients with typical bronchial carcinoid tumors. J Clin Endocrinol Metab 85: 3425-3430, 2000.
6. Cooper WA, Thourani VH, Gal AA, Lee RB, Mansour KA and Miller JI: The surgical spectrum of pulmonary neuroendocrine neoplasms. Chest 119: 14-18, 2001.
7. Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, Yokose T, Jiang SX, Inoue T, Nakagawa K, Tajima K and Nagai K: Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 24: 70-76, 2006.
8. Gustafsson BI, Kidd M, Chan A, Malfertheiner MV and Modlin IM: Bronchopulmonary neuroendocrine tumors. Cancer 113: 5-21, 2008.
9. Onuki N, Wistuba II, Travis WD, Virmani AK, Yashima K, Brambilla E, Hasleton P and Gazdar AF: Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer 85: 600-607, 1999.
10. Debelenko LV, Brambilla E, Agarwal SK, et al: Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet 6: 2285-2290, 1997.
11. Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441: 424-430, 2006.
12. Marinov M, Ziogas A, Pardo OE, Tan LT, Dhillon T, Mauri FA, Lane HA, Lemoine NR, Zangemeister-Wittke U, Seckl MJ and Arcaro A: AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. Clin Cancer Res 15: 1277-1287, 2009.
13. Bjornsti MA and Houghton PJ: The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4: 335-348, 2004.
14. Hay N and Sonenberg N: Upstream and downstream of mTOR. Genes Dev 18: 1926-1945, 2004.
15. Peterson RT, Beal PA, Comb MJ and Schreiber SL: FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. J Biol Chem 275: 7416-7423, 2000.
16. Akcakanat A, Sahin A, Shaye AN, Velasco MA and Meric-Bernstam F: Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer 112: 2352-2358, 2008.
17. Marinov M, Fischer B and Arcaro A: Targeting mTOR signaling in lung cancer. Crit Rev Oncol Hematol 63: 172-182, 2007.
18. Pitt SC, Chen H and Kunnimalaiyaan M: Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells. J Am Coll Surg 209: 82-88, 2009.
19. Zatelli MC, Minoia M, Martini C, Tagliati F, Ambrosio MR, Schiavon M, Buratto M, Calabrese F, Gentilin E, Cavallesco G, Berdondini L, Rea F and degli Uberti EC: Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. Endocr Relat Cancer 17: 719-729, 2010.
20. Tsurutani J, West KA, Sayyah J, Gills JJ and Dennis PA: Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res 65: 8423-8432, 2005.
21. Mamane Y, Petroulakis E, LeBacquer O and Sonenberg N: mTOR, translation initiation and cancer. Oncogene 25: 6416-6422, 2006.
22. Sobin LH, Gospodarowicz M and Wittekind C: TNM Classification of Malignant Tumours. 7th edition. Wiley-Blackwell, NJ, 2009.
23. Vignot S, Faivre S, Aguirre D and Raymond E: mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16: 525-537, 2005.
24. Krystal GW, Sulanke G and Litz J: Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther 1: 913-922, 2002.
25. Pandya KJ, Dahlberg S, Hidalgo M, Cohen RB, Lee MW, Schiller JH and Johnson DH; Eastern Cooperative Oncology Group (E1500): A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol 2: 1036-1041, 2007.
26. Massion PP, Taflan PM, Shyr Y, Rahman SM, Yildiz P, Shakthour B, Edgerton ME, Ninan M, Andersen JJ and Gonzalez AL: Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med 170: 1088-1094, 2004.
27. Shah T, Hochhauser D, Frow R, Quaglia A, Dhillon AP and Caplin ME: Epidermal growth factor receptor expression and activation in neuroendocrine tumours. J Neuroendocrinol 18: 355-360, 2006.
28. Dobashi Y, Suzuki S, Matsubara H, Kimura M, Endo S and Ooi A: Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas. Cancer 115: 107-118, 2009.
29. Righi L, Volante M, Rapa I, Tavaglione V, Inzani F, Pelosi G and Papotti M: Mammalian target of rapamycin (mTOR) signaling activation patterns in neuroendocrine tumors of the lung. Endocr Relat Cancer 17: 977-987, 2010.
30. Chadha KS, Khoury T, Yu J, Black JD, Gibbs JF, Kuvshinoff BW, Tan D, Brattain MG and Javle MM: Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol 13: 933-939, 2006.
31. Gingras AC, Raught B and Sonenberg N: Regulation of translation initiation by FRAP/mTOR. Genes Dev 15: 807-826, 2001.
32. Montagne J, Stewart MJ, Stocker H, Hafen E, Kozma SC and Thomas G: Drosophila S6 kinase: a regulator of cell size. Science 285: 2126-2129, 1999.
33. Gugger M, Burckhardt E, Kappeler A, Hirsiger H, Laissue JA and Mazzucchelli L: Quantitative expansion of structural genomic alterations in the spectrum of neuroendocrine lung carcinomas. J Pathol 196: 408-415, 2002.
34. Pinchot SN, Holen K, Sippel RS and Chen H: Carcinoid tumors. Oncologist 13: 1255-1269, 2008.